donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
TMO Thermo Fisher Scientific
548.270
+4.990+0.92%
Post Mkt Price
548.27000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/04/02(FY)2021/12/31(Q4)2021/12/31(Q3)2021/10/02
Investing cash flow
Cash flow from continuing investing activities
66.47% -670M -1352.45% -21.93B -2885.94% -18.69B -68.77% -616M
Net PPE purchase and sale
-2.41% -638M -70.74% -2.5B -40.17% -820M -42.47% -520M
Net business purchase and sale
97.02% -40M -50939.47% -19.4B -50974.29% -17.88B -- -94M
Net other investing changes
125% 8M -466.67% -34M -- 4M -- -2M
Cash from discontinued investing activities
Investing cash flow
66.47% -670M -1352.45% -21.93B -2885.94% -18.69B -68.77% -616M
Financing cash flow
Cash flow from continuing financing activities
35.15% -3.15B 586.24% 6.58B 17379.59% 8.47B 484.32% 3.04B
Net issuance payments of debt
64.05% -1.01B 224.39% 8.91B 859700% 8.6B 539.44% 3.12B
Net common stock issuance
0% -2B -33.33% -2B -- 0 -- 0
Cash dividends paid
-18.39% -103M -17.21% -395M -18.39% -103M -17.24% -102M
Proceeds from stock option exercised by employees
-90% 2M -20.41% 156M 37.5% 55M -6.45% 29M
Net other financing activities
-271.43% -36M 38.1% -91M -8000% -81M 72% -7M
Cash from discontinued financing activities
Financing cash flow
35.15% -3.15B 586.24% 6.58B 17379.59% 8.47B 484.32% 3.04B
Net cash flow
Beginning cash position
-56.55% 4.49B 326.75% 10.34B 59.15% 12.05B 20.52% 7.04B
Current changes in cash
66.88% -1.61B -178.04% -6.04B -382.92% -7.54B 226.93% 5.07B
Effect of exchange rate changes
-172.26% -99M 10.23% 194M -119.61% -20M -133.7% -61M
End cash Position
-50.4% 2.78B -56.55% 4.49B -56.55% 4.49B 59.15% 12.05B
Free cash flow
15.7% 1.56B -0.38% 6.79B -32.55% 1.86B -9.22% 2.13B
Investing cash flow
Cash flow from continuing investing activities
66.47% -670M -1352.45% -21.93B -2885.94% -18.69B -68.77% -616M
Net PPE purchase and sale
-2.41% -638M -70.74% -2.5B -40.17% -820M -42.47% -520M
Net business purchase and sale
97.02% -40M -50939.47% -19.4B -50974.29% -17.88B -- -94M
Net other investing changes
125% 8M -466.67% -34M -- 4M -- -2M
Cash from discontinued investing activities
Investing cash flow
66.47% -670M -1352.45% -21.93B -2885.94% -18.69B -68.77% -616M
Financing cash flow
Cash flow from continuing financing activities
35.15% -3.15B 586.24% 6.58B 17379.59% 8.47B 484.32% 3.04B
Net issuance payments of debt
64.05% -1.01B 224.39% 8.91B 859700% 8.6B 539.44% 3.12B
Net common stock issuance
0% -2B -33.33% -2B -- 0 -- 0
Cash dividends paid
-18.39% -103M -17.21% -395M -18.39% -103M -17.24% -102M
Proceeds from stock option exercised by employees
-90% 2M -20.41% 156M 37.5% 55M -6.45% 29M
Net other financing activities
-271.43% -36M 38.1% -91M -8000% -81M 72% -7M
Cash from discontinued financing activities
Financing cash flow
35.15% -3.15B 586.24% 6.58B 17379.59% 8.47B 484.32% 3.04B
Net cash flow
Beginning cash position
-56.55% 4.49B 326.75% 10.34B 59.15% 12.05B 20.52% 7.04B
Current changes in cash
66.88% -1.61B -178.04% -6.04B -382.92% -7.54B 226.93% 5.07B
Effect of exchange rate changes
-172.26% -99M 10.23% 194M -119.61% -20M -133.7% -61M
End cash Position
-50.4% 2.78B -56.55% 4.49B -56.55% 4.49B 59.15% 12.05B
Free cash flow
15.7% 1.56B -0.38% 6.79B -32.55% 1.86B -9.22% 2.13B
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
CEO: Casper, Marc N.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...